January 23, 2023 / CBD, Legal, Medical, News, North America, USA
OG Article: here.
This website may contain copyrighted material, the use of which has not been specifically authorized by the copyright holders. The material is made available on this website as a way to advance research and teaching related to critical media literacy and intercultural understanding, among other salient political and social issues. Through context, critical questioning, and educational framing, High at 9, therefore, creates a transformative use of copyrighted media. The material is presented for entirely non-profit educational purposes. There is no reason to believe that the featured media clips will in any way negatively affect the market value of the copyrighted works. For these reasons, we believe that the website is clearly covered under current fair use copyright laws.
We do not support any actions in which the materials on this site are used for purposes that extend beyond fair use.
The maker of CBD prescription drug Epidiolex has filed a lawsuit in the USA alleging patent infringement.
GW Research Ltd, a subsidiary of Ireland-based Jazz Pharmaceuticals, claims that more than 15 drugmakers are violating its patents as they develop generic versions of Epidiolex, the only pharmaceutical containing CBD that is approved by the U.S. Food and Drug Administration (FDA).
Those competitors have submitted Abbreviated New Drug Applications (ANDAs) in order to “commercially market generic versions of GW’s cannabidiol oral solution drug product,” GW said in the lawsuit, noting some of the patents do not expire until September 2025, while the others are still in force until July 2027.
Epidiolex received authorization for use in the treatment of two rare forms of epilepsy in young children in 2018 and 2020.